All News
Minority of Nonradiographic-Axial SpA Patients will Progress to Ankylosing Spondylitis
Wang and coworkers from the Rochester Epidemiology Project presented their findings at the annual Spondyloarthritis Research and Treatment Network.(SPARTAN) in Denver, CO.
Read ArticleCV Risk in RA: Is a New Measurement Tool the Answer?
A new expanded cardiovascular (CV) risk calculator for use in patients with rheumatoid arthritis (RA) has been developed to take into account disease-specific factors that can worsen risk, researchers reported.
Read ArticleHeel Pain, Uveitis, TB, Vitamin D, Hidradenitis: July 2015 top social media news
In July 2015, RheumNow published 73 tweets about impactful news, research and teaching points that I feel will have an impact on the rheumatology community. We had a reach (impressions) of 49,900, 63 mentions, and 1277 visits to RheumNow.com to check out what we publish.
Read ArticleAstraZeneca Pushes Forward on Brodalumab Development
Despite Amgen's withdrawal as a co-developer of brodalumab, the anti-IL17A monoclonal antibody, AstraZeneca has announced it will push its plan to develop the drug. Brodalumab is currently in phase III trials for use in psoriasis, psoriatic arthritis and ankylosing spondylitis.
Read ArticleCymbalta Lawsuit Alleges Downplay of Withdrawal Symptoms
An estimated 250 people have filed lawsuits against Lilly claiming the company failed to warn users of Cymbalta that they may suffer withdrawal symptoms if the drug was stopped abruptly, including suicidal thoughts and electric shock-like sensations.
Read Article10 Year Study Identifies Predictors of Skin Progression in Systemic Sclerosis
The European Scleroderma Trials and Research (EUSTAR) cohort has reported the results of their prospective study to identify onset symptoms and risk factors for skin sclerosis and digital ulcers (DUs) in early onset systemic sclerosis (SSc) patients.
Read ArticleBidirectional Association Between Uveitis and Psoriatic Disease
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
Read ArticleSafety Reports in the News
Can We Do Better than FAERS? Brian Overstreet (of Adverseevents.com) has written on MedPageToday.com about the current state of adverse event reporting.
Read ArticleACTEMRA Gets "Breakthrough" Status from the FDA for Scleroderma
The FASSCINATE study presented at EULAR 2015 was instrumental in tocilizumab (TCZ) getting a nod from the FDA to develop TCZ for scleroderma.
Read ArticleVitamin D Fails in Postmenopausal Osteoporosis Prevention
JAMA reports that investigators from the University of Wisconsin in Madison studied the impact of vitamin D supplements on 230 women who were at least five years past menopause but no older than 75, and without osteoporo
Read ArticleLegionella Outbreak in NYC
An outbreak of Legionnaires' disease has killed four people and sickened 65 in the Bronx section of New York City since July 10, according to New York City health officials. This Legionnaires' outbreak is now more than five times the number of cases recorded in the last outbre
Read ArticleCDC Report: 22% of USA Population is Disabled
CDC has released the findings of its 2013 Behavioral Risk Factor Surveillance System (BRFSS), with 5 questions addressing different forms of disability - vision, cognition, mobility, self-care, and independent living. Overall, 22.2% of U.S. adults (53,316,677 persons) reported any disability.
Read ArticleNSAIDs are Risky in Patients with Chronic Kidney Disease
Little is known about what happens when NSAIDs are used in patients with chronic kidned disease (CKD), especially those with hypertension.
Read ArticleLipid Levels and CV Events in RA
Rheumatoid arthritis not only affects the joints but can also increase risk for cardiovascular disease. The mechanism of the increased risk of cardiovascular disease in rheumatoid arthritis remains uncertain.
Read ArticleB cell Inhibition with Epratuzumab Fails in Two Phase III Lupus Trials
Targeting B cells in systemic lupus erythematosus, the prototypic autoimmune disorder, has long been an attractive target for researchers. Despite negative trials with rituximab and the limited success of belimumab, efforts to inhibit B cell activity have continued.
Read ArticleMen and Blacks Undertreated for Osteoporosis
Using claims data from 36,965 patients in an Indiana database, researchers found women (OR 1.86) and non-black patients (OR 1.52) were more likely to be treated (p<0.001) for osteoporosis.
Read ArticleGut Dysbiosis in RA Reflects Activity, Serology and Response
Using a metagenome-wide association study (MGWAS) of fecal, dental and salivary samples from rheumatoid arthritis and healthy controls, Zhang et al showed that gut and oral microbiomes are highly concordant and that in RA there is a distinct dysbiosis with less Haemophilus spp.
Read ArticleIs Morning Stiffness Important?
Morning stiffness? An oft-asked question, but does it have reliable discriminatory value?
Read ArticleNot All Placebos are Equal: The Needle is Mightier than the Pill
Placebos are necessary to determine the “true effect” of any medical intervention. As such, they have become the cornerstone of evidence-based medicine, randomized controlled clinical trials and novel drug development.
Read Article2015 Guidelines for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing form of interstitial pneumonia, with poor survival rates of nearly 50% at 3 years.
Read Article